The goal of the Analytical Cytometry Core (ACC) is to provide the COHCCC members, through its facilities, leading-edge equipment and experienced operators to measure properties of cells and their components, isolate those cells and their components and present the data acquired for internal analysis and external review. Flow cytometry instrumentation available through this core resource includes: 3 high speed cell sorters (MoFlo, BD FACS Aria SORP and BD FACS Aria 111), and 4 analytical cytometers (Cyan, Gallios, LSR Fortessa and C6). The flow cytometry instrumentation provides investigators with the tools to analyze and isolate cells at speeds of up to 20,000 cells/second based on multiple fluorescent labels (up to 18) and light scatter properties with high yield (up to 90% based on speed) and extreme purity (99%). Additionally, the BD Aha 11 SORP is contained in a biosafety cabinet and allows users to sort live (potentially infectious) samples. All instrumentation in the ACC is subject to either daily (sorters and Fortessa) or weekly (Gallios, CyAn, and C6) quality control assessment and routine preventive maintenance and calibration. All data generated in the ACC is available through the institutional cyber-infrastructure network for further analysis and preparation for presentation or publication. Network based data processing software is offered by the core and a Laboratory Information Management System (LIMS) is being developed to help track experiment related meta data and archived file retrieval. Another key role of ACC is to provide flow cytometry training from basic theory, experimental design, software usage and operation of the cytometers to COHCCC members.

Public Health Relevance

The overall goal of the Analytical Cytometry Core facility is to provide leading-edge equipment and experienced operators to measure properties of cells and their components, isolate those cells and present the data acquired for analysis and review. This goal promotes the Cancer Center's mission of developing innovative new disease-fighting strategies in the battle against cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Salhotra, A; Tsai, N; Thomas, S H et al. (2015) Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50:139-41
Ali, H; Palmer, J; Eroglu, Z et al. (2015) Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplant 50:307-9
Behrendt, Carolyn E; Hurria, Arti; Tumyan, Lusine et al. (2014) Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. J Natl Compr Canc Netw 12:1579-85
Yang, Lixin; Perez, Aldwin Apollo; Fujie, Sayuri et al. (2014) Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14:124
Gillis, Peter A; Hernandez-Alvarado, Nelmary; Gnanandarajah, Josephine S et al. (2014) Development of a novel, guinea pig-specific IFN-? ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 32:3963-70
Chen, Shiuan; Zhou, Dujin; Hsin, Li-Yu et al. (2014) AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci 139:198-209
Bhatia, Smita; Landier, Wendy; Hageman, Lindsey et al. (2014) 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 124:2345-53
Sun, Virginia; Grant, Marcia; McMullen, Carmit K et al. (2014) From diagnosis through survivorship: health-care experiences of colorectal cancer survivors with ostomies. Support Care Cancer 22:1563-70

Showing the most recent 10 out of 912 publications